Search Results - "Keresztes, David"

Cellular forgetting, desensitisation, stress and ageing in signalling networks. When do cells refuse to learn more? by Veres, Tamás, Kerestély, Márk, Kovács, Borbála M., Keresztes, Dávid, Schulc, Klára, Seitz, Erik, Vassy, Zsolt, Veres, Dániel V., Csermely, Peter

“…Recent findings show that single, non-neuronal cells are also able to learn signalling responses developing cellular memory. In cellular learning nodes of…”
Get full text

Proteome profiling of enzalutamide‐resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration‐resistant prostate cancer by Csizmarik, Anita, Keresztes, Dávid, Nagy, Nikolett, Bracht, Thilo, Sitek, Barbara, Witzke, Kathrin, Puhr, Martin, Tornyi, Ilona, Lázár, József, Takács, László, Kramer, Gero, Sevcenco, Sabina, Maj‐Hes, Agnieszka, Jurányi, Zsolt, Hadaschik, Boris, Nyirády, Péter, Szarvas, Tibor

“…Enzalutamide (ENZA) is a frequently used therapy in metastatic castration‐resistant prostate cancer (mCRPC). Baseline or acquired resistance to ENZA have been…”
Get full text

Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer by Csizmarik, Anita, Nagy, Nikolett, Keresztes, Dávid, Váradi, Melinda, Bracht, Thilo, Sitek, Barbara, Witzke, Kathrin, Puhr, Martin, Tornyi, Ilona, Lázár, József, Takács, László, Kramer, Gero, Sevcenco, Sabina, Maj-Hes, Agnieszka, Hadaschik, Boris, Nyirády, Péter, Szarvas, Tibor

“…Background Abiraterone (Abi) is an androgen receptor signaling inhibitor that significantly improves patients’ life expectancy in metastatic prostate cancer…”
Get full text

Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration‐resistant prostate cancer by Keresztes, Dávid, Csizmarik, Anita, Nagy, Nikolett, Módos, Orsolya, Fazekas, Tamás, Bracht, Thilo, Sitek, Barbara, Witzke, Kathrin, Puhr, Martin, Sevcenco, Sabina, Kramer, Gero, Shariat, Shahrokh, Küronya, Zsófia, Takács, László, Tornyi, Ilona, Lázár, József, Hadaschik, Boris, Lászik, András, Szűcs, Miklós, Nyirády, Péter, Szarvas, Tibor

“…Baseline or acquired resistance to docetaxel (DOC) represents a significant risk for patients with metastatic prostate cancer (PC). In the last years, novel…”
Get full text

Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer by Szarvas, Tibor, Sevcenco, Sabina, Módos, Orsolya, Keresztes, Dávid, Nyirády, Péter, Kubik, András, Romics, Miklós, Kovalszky, Ilona, Reis, Henning, Hadaschik, Boris, Shariat, Shahrokh F., Kramer, Gero

“…Docetaxel chemotherapy is a standard treatment for castration-resistant prostate cancer (CRPC). Rapidly expanding treatment options for CRPC provide reasonable…”
Get full text

Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration‐resistant prostate cancer by Szarvas, Tibor, Sevcenco, Sabina, Módos, Orsolya, Keresztes, Dávid, Nyirády, Péter, Csizmarik, Anita, Ristl, Robin, Puhr, Martin, Hoffmann, Michèle J., Niedworok, Christian, Hadaschik, Boris, Maj‐Hes, Agnieszka, Shariat, Shahrokh F., Kramer, Gero

“…Objective To assess the predictive value of pre‐chemotherapy matrix metalloproteinase 7 (MMP‐7), soluble Fas (sFas) and Fas ligand (FasL) serum levels, as well…”
Get full text

Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas by Varadi, Melinda, Nagy, Nikolett, Reis, Henning, Hadaschik, Boris, Niedworok, Christian, Modos, Orsolya, Szendroi, Attila, Ablat, Jason, Black, Peter C., Keresztes, David, Csizmarik, Anita, Olah, Csilla, Gaisa, Nadine T., Kiss, Andras, Timar, Jozsef, Toth, Erika, Csernak, Erzsebet, Gerstner, Arpad, Mittal, Vinay, Karkampouna, Sofia, Kruithof de Julio, Marianna, Gyorffy, Balazs, Bedics, Gabor, Rink, Michael, Fisch, Margit, Nyirady, Peter, Szarvas, Tibor

“…Objective Administration of targeted therapies provides a promising treatment strategy for urachal adenocarcinoma (UrC) or primary bladder adenocarcinoma…”
Get full text

Molecular underpinnings of systemic treatment resistance in metastatic castration-resistant prostate cancer by Szarvas, Tibor, Csizmarik, Anita, Nagy, Nikolett, Keresztes, Dávid, Váradi, Melinda, Küronya, Zsófia, Riesz, Péter, Nyirády, Péter

“…In the last few years, several new drugs with various mechanisms of action have been approved for the treatment of castration-resistant prostate cancer. Due to…”
Get more information

Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas by Reis, Henning, van der Vos, Kristan E., Niedworok, Christian, Herold, Thomas, Módos, Orsolya, Szendrői, Attila, Hager, Thomas, Ingenwerth, Marc, Vis, Daniël J., Behrendt, Mark A., de Jong, Jeroen, van der Heijden, Michiel S., Peyronnet, Benoit, Mathieu, Romain, Wiesweg, Marcel, Ablat, Jason, Okon, Krzysztof, Tolkach, Yuri, Keresztes, David, Nagy, Nikolett, Bremmer, Felix, Gaisa, Nadine T., Chlosta, Piotr, Kriegsmann, Joerg, Kovalszky, Ilona, Timar, József, Kristiansen, Glen, Radzun, Heinz‐Joachim, Knüchel, Ruth, Schuler, Martin, Black, Peter C., Rübben, Herbert, Hadaschik, Boris A., Schmid, Kurt Werner, van Rhijn, Bas W.G., Nyirády, Péter, Szarvas, Tibor

“…Urachal cancer (UrC) is a rare but aggressive malignancy often diagnosed in advanced stages requiring systemic treatment. Although cytotoxic chemotherapy is of…”
Get full text

Prevalence of APC and PTEN Alterations in Urachal Cancer by Nagy, Nikolett, Reis, Henning, Hadaschik, Boris, Niedworok, Christian, Módos, Orsolya, Szendrői, Attila, Bíró, Krisztina, Hager, Thomas, Herold, Thomas, Ablat, Jason, Black, Peter C., Okon, Krzysztof, Tolkach, Yuri, Csizmarik, Anita, Oláh, Csilla, Keresztes, David, Bremmer, Felix, Gaisa, Nadine T., Kriegsmann, Joerg, Kovalszky, Ilona, Kiss, András, Tímár, József, Szász, Marcell A., Rink, Michael, Fisch, Margit, Nyirády, Péter, Szarvas, Tibor

“…Urachal carcinoma (UrC) is a rare tumor with remarkable histological and molecular similarities to colorectal cancer (CRC). Adenomatous polyposis coli ( APC)…”
Get full text

P athogenic and targetable genetic alterations in 70 urachal adenocarcinomas by Reis, Henning, van der Vos, Kristan E., Niedworok, Christian, Herold, Thomas, Módos, Orsolya, Szendrői, Attila, Hager, Thomas, Ingenwerth, Marc, Vis, Daniël J., Behrendt, Mark A., de Jong, Jeroen, van der Heijden, Michiel S., Peyronnet, Benoit, Mathieu, Romain, Wiesweg, Marcel, Ablat, Jason, Okon, Krzysztof, Tolkach, Yuri, Keresztes, David, Nagy, Nikolett, Bremmer, Felix, Gaisa, Nadine T., Chlosta, Piotr, Kriegsmann, Joerg, Kovalszky, Ilona, Timar, József, Kristiansen, Glen, Radzun, Heinz‐Joachim, Knüchel, Ruth, Schuler, Martin, Black, Peter C., Rübben, Herbert, Hadaschik, Boris A., Schmid, Kurt Werner, van Rhijn, Bas W.G., Nyirády, Péter, Szarvas, Tibor

“…Urachal cancer (UrC) is a rare but aggressive malignancy often diagnosed in advanced stages requiring systemic treatment. Although cytotoxic chemotherapy is of…”
Get full text

Cellular forgetting, desensitisation, stress and aging in signalling networks. When do cells refuse to learn more? by Veres, Tamas, Kerestely, Mark, Kovacs, Borbala M, Keresztes, David, Schulc, Klara, Seitz, Erik, Vassy, Zsolt, Veres, Daniel V, Csermely, Peter

“…Cellular and Molecular Life Sciences (2024) 81,97 Recent findings show that single, non-neuronal cells are also able to learn signalling responses developing…”
Get full text

Syndecan-1 shedding circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer by Szarvas, Tibor, Sevcenco, Sabina, Módos, Orsolya, Keresztes, Dávid, Nyirády, Péter, Kubik, András, Romics, Miklós, Kovalszky, Ilona, Reis, Henning, Hadaschik, Boris, Shariat, Shahrokh F, Kramer, Gero

“…Docetaxel chemotherapy is a standard treatment for castration-resistant prostate cancer (CRPC). Rapidly expanding treatment options for CRPC provide reasonable…”
Get full text